Sign in
4

Changes in Ownership

BioXcel Therapeutics, Inc. Filed Acc 0001104659-22-128367

CEO and President sold 60,000 shares at an average $19.69 ($1,181,498)

  • CEO and President acquired 60,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Mehta Vimal · CEO and President

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2022-12-15 Exercise or conversion : show line 1 in the form +30,000 $0.41 $12,300 39,957 D
2022-12-15 Sale : show line 2 in the form −22,794 $19.86 $452,689 17,163 D
2022-12-15 Sale : show line 3 in the form −7,206 $20.19 $145,489 9,957 D
2022-12-16 Exercise or conversion : show line 4 in the form +30,000 $0.41 $12,300 39,957 D
2022-12-16 Sale : show line 5 in the form −20,113 $19.21 $386,371 19,844 D
2022-12-16 Sale : show line 6 in the form −9,887 $19.92 $196,949 9,957 D
Open-market sales · 60,000 sh · avg $19.69 · $1,181,498

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2022-12-15 Exercise or conversion : show line 7 in the form Stock Option (Right to Buy) −30,000 444,000 D
2022-12-16 Exercise or conversion : show line 8 in the form Stock Option (Right to Buy) −30,000 414,000 D
Loading xslF345X03/tm2233011-1_4seq1.xml…